Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in inflammatory processes. Hypercoagulability is defined as the tendency to develop thrombosis according to fibrinogen and/or D dimer levels. Nephrotic syndrome is also considered to be a hypercoagulable state. The aim of this study is to investigate the association of soluble PDPN/CLEC-2 with hypercoagulability in nephrotic syndrome. Thirty-five patients with nephrotic syndrome and twenty-seven healthy volunteers were enrolled. PDPN, CLEC-2 and GPVI concentrations were tested by enzyme-linked immunosorbent assay (ELISA). Patients with nephrotic syndrome showed higher serum levels of PDPN and GPVI in comparison to healthy controls (P < .001, P = .001). PDPN levels in patients with nephrotic syndrome were significantly correlated with GPVI (r = 0.311; P = .025), hypoalbuminemia (r = −0.735; P < .001), hypercholesterolemia (r = 0.665; P < .001), hypertriglyceridemia (r = 0.618; P < .001), fibrinogen (r = 0.606; P < .001) and D-dimer (r = 0.524; P < .001). Area under the curve (AUC) for the prediction of hypercoagulability in nephrotic syndrome using PDPN was 0.886 (95% CI 0.804-0.967, P < .001). Cut-off value for the risk probability was 5.88 ng/ml. The sensitivity of PDPN in predicting hypercoagulability was 0.806, and the specificity was 0.846. When serum PDPN was >5.88 ng/ml, the risk of hypercoagulability was significantly increased in nephrotic syndrome (OR = 22.79, 95% CI 5.92-87.69, P < .001). In conclusion, soluble PDPN levels were correlated with hypercoagulability in nephrotic syndrome. PDPN has the better predictive value of hypercoagulability in nephrotic syndrome as well as was a reliable indicator of hypercoagulable state.

Podoplanin (PDPN) 通过与血小板上的 C 型凝集素样受体 2 (CLEC-2) 相互作用来促进血小板聚集和活化。上调的 PDPN 和血小板 CLEC-2 之间的相互作用会刺激静脉血栓形成。PDPN 被确定为炎症过程中凝血和血栓形成的危险因素。高凝状态定义为根据纤维蛋白原和/或 D 二聚体水平形成血栓形成的趋势。肾病综合征也被认为是一种高凝状态。本研究的目的是探讨可溶性 PDPN/CLEC-2 与肾病综合征高凝状态的关系。招募了 35 名肾病综合征患者和 27 名健康志愿者。通过酶联免疫吸附试验（ELISA）测试PDPN、CLEC-2和GPVI浓度。P  < .001，P  = .001）。肾病综合征患者的 PDPN 水平与 GPVI (r = 0.311; P  = .025)、低白蛋白血症 (r = -0.735; P  < .001)、高胆固醇血症 (r = 0.665; P  < .001)、高甘油三酯血症 (r = 0.665; P < .001) 显着相关。 r = 0.618；P  < .001）、纤维蛋白原（r = 0.606；P  < .001）和 D-二聚体（r = 0.524；P  < .001）。使用 PDPN 预测肾病综合征高凝状态的曲线下面积 (AUC) 为 0.886 (95% CI 0.804-0.967, P < .001)。风险概率的临界值为 5.88 ng/ml。PDPN预测高凝状态的敏感性为0.806，特异性为0.846。当血清 PDPN >5.88 ng/ml 时，肾病综合征患者的高凝状态风险显着增加（OR = 22.79，95% CI 5.92-87.69，P  < .001）。总之，可溶性 PDPN 水平与肾病综合征的高凝状态相关。PDPN对肾病综合征的高凝状态具有较好的预测价值，是高凝状态的可靠指标。